Vaccination against nicotine: an emerging therapy for tobacco dependence

Maurer, Patrik; Bachmann, Martin F.

doi:10.1517/13543784.16.11.1775

Cited by 68 publications

(51 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using this approach to vaccine design, we have previously demonstrated that levels of neutralizing Ab responses against self-proteins can be induced that are high enough to show therapeutic effectiveness in mice (31)(32)(33)(34)(35). We have also demonstrated that efficacy established in animal models can be translated into efficacy in humans (47,48). An important safety feature and advantage of VLP-based vaccines is that autoantibodies can be induced without the addition of powerful adjuvants.…”

Section: Discussionmentioning

confidence: 99%

A Virus-Like Particle-Based Anti-Nerve Growth Factor Vaccine Reduces Inflammatory Hyperalgesia: Potential Long-Term Therapy for Chronic Pain

Röhn¹,

Ralvenius

Paul

et al. 2011

The Journal of Immunology

View full text Add to dashboard Cite

Chronic pain resulting from inflammatory and neuropathic disorders causes considerable economic and social burden. For a substantial proportion of patients, conventional drug treatments do not provide adequate pain relief. Consequently, novel approaches to pain management, involving alternative targets and new therapeutic modalities compatible with chronic use, are being sought. Nerve growth factor (NGF) is a major mediator of chronic pain. Clinical testing of NGF antagonists is ongoing, and clinical proof of concept has been established with a neutralizing mAb. Active immunization, with the goal of inducing therapeutically effective neutralizing autoreactive Abs, is recognized as a potential treatment option for chronic diseases. We have sought to determine if such a strategy could be applied to chronic pain by targeting NGF with a virus-like particle (VLP)-based vaccine. A vaccine comprising recombinant murine NGF conjugated to VLPs from the bacteriophage Qβ (NGFQβ) was produced. Immunization of mice with NGFQβ induced anti-NGF–specific IgG Abs capable of neutralizing NGF. Titers could be sustained over 1 y by periodic immunization but declined in the absence of boosting. Vaccination with NGFQβ substantially reduced hyperalgesia in collagen-induced arthritis or postinjection of zymosan A, two models of inflammatory pain. Long-term NGFQβ immunization did not change sensory or sympathetic innervation patterns or induce cholinergic deficits in the forebrain, nor did it interfere with blood-brain barrier integrity. Thus, autovaccination targeting NGF using a VLP-based approach may represent a novel modality for the treatment of chronic pain.

show abstract

Section: Discussionmentioning

confidence: 99%

A Virus-Like Particle-Based Anti-Nerve Growth Factor Vaccine Reduces Inflammatory Hyperalgesia: Potential Long-Term Therapy for Chronic Pain

Röhn¹,

Ralvenius

Paul

et al. 2011

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…Some progress is being made in developing vaccines which modulate the course of diabetes and hypertension [42]. Vaccination against addiction, including smoking, is also feasible, although very high antibody concentrations are required to achieve an effect [43], and there are early results suggesting that vaccination against Alzheimer's disease might slow the progress of this condition [44]. In the coming decades, vaccination is likely to expand its scope beyond prevention of the common infections of childhood which has been its main success so far.…”

Section: The Long-term Future Of Vaccinationmentioning

confidence: 99%

The contribution of vaccination to global health: past, present and future

Greenwood

2014

Phil. Trans. R. Soc. B

744

516

View full text Add to dashboard Cite

Vaccination has made an enormous contribution to global health. Two major infections, smallpox and rinderpest, have been eradicated. Global coverage of vaccination against many important infectious diseases of childhood has been enhanced dramatically since the creation of WHO's Expanded Programme of Immunization in 1974 and of the Global Alliance for Vaccination and Immunization in 2000. Polio has almost been eradicated and success in controlling measles makes this infection another potential target for eradication. Despite these successes, approximately 6.6 million children still die each year and about a half of these deaths are caused by infections, including pneumonia and diarrhoea, which could be prevented by vaccination. Enhanced deployment of recently developed pneumococcal conjugate and rotavirus vaccines should, therefore, result in a further decline in childhood mortality. Development of vaccines against more complex infections, such as malaria, tuberculosis and HIV, has been challenging and achievements so far have been modest. Final success against these infections may require combination vaccinations, each component stimulating a different arm of the immune system. In the longer term, vaccines are likely to be used to prevent or modulate the course of some non-infectious diseases. Progress has already been made with therapeutic cancer vaccines and future potential targets include addiction, diabetes, hypertension and Alzheimer's disease.

show abstract

“…Upon inhalation of cigarette smoke, nicotine passes into the bloodstream and, within seconds, crosses the bloodbrain barrier to enter the brain, where it causes the release of dopamine and exerts its addictive effects. Nicotine addiction vaccines work by causing the immune system to produce nicotine antibodies, which bind to nicotine and prevent it from crossing the bloodbrain barrier [Maurer and Bachmann, 2007]. This removes the pleasurable stimulus in the brain that is normally caused by nicotine.…”

Section: Nicotine Vaccinesmentioning

confidence: 99%

Therapeutic advances in the treatment of nicotine addiction: present and future

Casella¹,

Caponnetto²,

Polosa

2010

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

While the proportion of the adult population that smokes has declined steadily in several westernized societies, the rate of successful quit attempts is still low. This is because smokers develop nicotine dependence, a powerful addiction that may require multiple attempts and long-term treatment to achieve enduring abstinence. Currently available first-line agents for smoking cessation therapy include nicotine replacement therapy (available in several formulations, including transdermal patch, gum, nasal spray, inhaler, and lozenge), bupropion (an atypical antidepressant), and varenicline (a partial agonist of the a4b2 nicotinic acetylcholine receptor that was recently developed and approved specifically for smoking cessation therapy). Second-line agents are nortriptyline (a tricyclic antidepressant agent) and the antihypertensive agent clonidine. With the exception of varenicline, which has been shown to offer significant improvement in abstinence rates over bupropion, all of the available treatments appear similarly effective. The adverse event profiles of nortriptyline and clonidine make them more appropriate for second-line therapy, when first-line treatments have failed or are not tolerated. However, the currently marketed smoking cessation drugs reportedly lack high levels of efficacy, particularly in real-life settings. New medications and vaccines with significant clinical advantage are now in the advanced stage of development and offer promise. These include nicotine vaccines and monoamine type B inhibitors. In this review article we discuss current and emerging pharmacotherapies for tobacco dependence focusing on their mechanisms of action, efficacy and adverse event profiles.

show abstract

Vaccination against nicotine: an emerging therapy for tobacco dependence

Cited by 68 publications

References 47 publications

A Virus-Like Particle-Based Anti-Nerve Growth Factor Vaccine Reduces Inflammatory Hyperalgesia: Potential Long-Term Therapy for Chronic Pain

A Virus-Like Particle-Based Anti-Nerve Growth Factor Vaccine Reduces Inflammatory Hyperalgesia: Potential Long-Term Therapy for Chronic Pain

The contribution of vaccination to global health: past, present and future

Therapeutic advances in the treatment of nicotine addiction: present and future

Contact Info

Product

Resources

About